CRI Worldwide and Lifetree Clinical Research Announce New Company Name: CRI Lifetree
CRI Worldwide, a specialized research organization conentating in psychiatry, pediatrics, pain, and neurology, which recently acquired Lifetree Clinical Research, has united the two companies under the new name, CRI Lifetree. Accompanying the new name is its strategically focused tagline, “Innovative Solutions. Reliable Results.”
The company integrates CRI’s experience in psychiatry and expertise in complex studies with Lifetree’s clinical trial management and site expertise in Phase I-III pain management and abuse liability studies. Bringing the companies together under one unified name streamlines all branding, communication, and SOPs and processes across the two companies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
